Steady-state volume of distribution of fenelidone

As a selective mineralocorticoid receptor antagonist, finerenone (Finerenone) has unique pharmacological properties. Unlike nonselective mineralocorticoid receptor antagonists, fenelidone specifically targets and blocks the mineralocorticoid receptor, minimizing off-target effects. This selectivity contributes to its favorable therapeutic efficacy and potential for improved safety and efficacy compared with similar drugs.

Concerning the steady-state volume of distribution of fenelinone, it is necessary to understand the distribution of the drug in the body. Steady-state volume of distribution (Vdss) refers to the distribution relationship between the drug and the tissues and fluids in the body when it reaches steady state. For fenelide, the specific value of its steady-state volume of distribution will be affected by a variety of factors, including the drug's protein binding rate, lipid solubility, molecular size, etc. It is understood that the distribution volume of fenelinone at steady state is 52.6 liters.

Finelidone is used as an adjunct to treatment to reduce the risk of end-stage renal disease and sustained decline in glomerular filtration rate (eGFR), as well as the risk of cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure. Nonsteroidal selective mineralocorticoid receptor antagonists (MRA). It is available as an oral tablet and the recommended starting dose of fenelidone is 20 mg once daily for patients with an eGFR of at least 60 mL/min/1.73m2 and 10 mg once daily for patients with an eGFR of at least 25 to <60 mL/min/1.73m2. Four weeks after initiating or reinitiating or discontinuing fenglitazone therapy, serum potassium and eGFR should be remeasured to determine whether to continue fenglitazone therapy and adjust the dose. Thereafter, serum potassium should be remeasured periodically and as needed based on patient characteristics and serum potassium levels.